Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Th 302
2. Th-302
3. Th302 Cpd
1. Th-302
2. 918633-87-1
3. Th302
4. Th 302
5. Hap-302
6. N,n'-bis(2-bromoethyl)phosphorodiamidic Acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl Ester
7. 2-bromo-n-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine
8. 8a9rz3hn8w
9. Compound 3b
10. Th-302; Evofosfamide;hap-302
11. Phosphorodiamidic Acid, N,n'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1h-imidazol-5-yl)methyl Ester
12. Phosphorodiamidic Acid, N,n'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1h-imidazol-5-yl)methyl Ester.
13. Evofosfamide [usan:inn]
14. Unii-8a9rz3hn8w
15. Evofosfamide(th 302)
16. Evofosfamide(th-302)
17. Evofosfamide [inn]
18. Evofosfamide [jan]
19. Evofosfamide [usan]
20. Evofosfamide [who-dd]
21. Chembl260046
22. Evofosfamide (jan/usan/inn)
23. Gtpl8695
24. Schembl2357174
25. Schembl15691894
26. Dtxsid60238721
27. Amy16615
28. Bcp06074
29. Ex-a1740
30. Bdbm50543112
31. S2757
32. Zinc29053729
33. Akos026673946
34. Ccg-269225
35. Cs-0616
36. Db06091
37. Sb17116
38. Ac-29025
39. As-74462
40. Hy-10535
41. Ft-0696771
42. J3.504.735b
43. D10704
44. A901406
45. J-523214
46. Q7670203
47. (1-methyl-2-nitro-1h-imidazol-5-yl)methyl N,n'-bis(2-bromoethyl)diamidophosphate
48. (1-methyl-2-nitro-1h-imidazole-5-yl)methyl N,n'-bis(2-bromoethyl) Diamidophosphate
49. 1-methyl-2-nitro-l H-imidazole-5-yl) N,n-bis(2-bromoethyl)diamidophosphate
50. (2-bromoethyl)({[(2-bromoethyl)amino][(1-methyl-2-nitro-1h-imidazol-5-yl)methoxy]phosphoryl})amine
51. Th302n,n'-bis(2-bromoethyl)phosphorodiamidic Acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl Ester
Molecular Weight | 449.04 g/mol |
---|---|
Molecular Formula | C9H16Br2N5O4P |
XLogP3 | 0.6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 9 |
Exact Mass | 448.92862 g/mol |
Monoisotopic Mass | 446.93067 g/mol |
Topological Polar Surface Area | 114 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 374 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in solid tumors.
TH-302 combines a 2-nitroimidazole oxygen-sensing trigger with a masked DNA crosslinker. Upon activation in oxygen deficient zones, TH-302 is converted selectively to the drug's active form, dibromo isophosphoramide mustard, a potent alkylator. TH-302 targets levels of severe hypoxia that are found in tumors but are rare in normal tissues - this is how selective targeting of the tumor occurs. After conversion to the active form of the drug, the hypoxic cells are exposed to high concentrations of released cytotoxic agent, which can also diffuse into the adjacent regions of the tumor.
ABOUT THIS PAGE
30
PharmaCompass offers a list of Evofosfamide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Evofosfamide manufacturer or Evofosfamide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Evofosfamide manufacturer or Evofosfamide supplier.
PharmaCompass also assists you with knowing the Evofosfamide API Price utilized in the formulation of products. Evofosfamide API Price is not always fixed or binding as the Evofosfamide Price is obtained through a variety of data sources. The Evofosfamide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Evofosfamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Evofosfamide, including repackagers and relabelers. The FDA regulates Evofosfamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Evofosfamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Evofosfamide supplier is an individual or a company that provides Evofosfamide active pharmaceutical ingredient (API) or Evofosfamide finished formulations upon request. The Evofosfamide suppliers may include Evofosfamide API manufacturers, exporters, distributors and traders.
Evofosfamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Evofosfamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Evofosfamide GMP manufacturer or Evofosfamide GMP API supplier for your needs.
A Evofosfamide CoA (Certificate of Analysis) is a formal document that attests to Evofosfamide's compliance with Evofosfamide specifications and serves as a tool for batch-level quality control.
Evofosfamide CoA mostly includes findings from lab analyses of a specific batch. For each Evofosfamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Evofosfamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Evofosfamide EP), Evofosfamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Evofosfamide USP).